Intravitreal Interleukin 6 Inhibitors for Uveitic Macular Edema

This Viewpoint discusses the results of a phase 1 study evaluating the intravitreal interleukin 6 inhibitor vamikibart for the treatment of uveitic macular edema.

Corresponding Author: Stephanie M. Llop, MD, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL 33136 (sxl1789@med.miami.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.